ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
8
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
8
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Doxorubicin Hydrochloride Injection Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: October 2025
|
Report Code: QYRE-Auto-10C17319
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Doxorubicin Hydrochloride Injection Market Research Report 2024
BUY CHAPTERS

Global Doxorubicin Hydrochloride Injection Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-10C17319
Report
October 2025
Pages:141
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Fresenius Kabi
Mylan NV
TEVA
Advacare Pharma
Taj Pharma
Getwell Pharma

Doxorubicin Hydrochloride Injection Market

The global Doxorubicin Hydrochloride Injection market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Doxorubicin is an anthracycline type of chemotherapy that is used alone or with other treatments/medications to treat several different types of cancer.
From a downstream perspective, Hospital accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Doxorubicin Hydrochloride Injection leading manufacturers including Hikma, Pfizer, Fresenius Kabi, Mylan, Sagent, Teva, AdvaCare Pharma, TAJ Pharma, Getwell Pharma, etc., dominate supply; the top five capture approximately % of global revenue, with Hikma leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Doxorubicin Hydrochloride Injection market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Doxorubicin Hydrochloride Injection Market Report

Report Metric Details
Report Name Doxorubicin Hydrochloride Injection Market
Segment by Type
  • 5ml/vial
  • 10ml/vial
  • 50ml/vial
  • Others
Segment by Application
  • Hospital
  • Specialty Clinics
  • Others
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Hikma, Pfizer, Fresenius Kabi, Mylan, Sagent, Teva, AdvaCare Pharma, TAJ Pharma, Getwell Pharma
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Doxorubicin Hydrochloride Injection study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
  • Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 15: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Doxorubicin Hydrochloride Injection Market report?

Ans: The main players in the Doxorubicin Hydrochloride Injection Market are Hikma, Pfizer, Fresenius Kabi, Mylan, Sagent, Teva, AdvaCare Pharma, TAJ Pharma, Getwell Pharma

What are the Application segmentation covered in the Doxorubicin Hydrochloride Injection Market report?

Ans: The Applications covered in the Doxorubicin Hydrochloride Injection Market report are Hospital, Specialty Clinics, Others

What are the Type segmentation covered in the Doxorubicin Hydrochloride Injection Market report?

Ans: The Types covered in the Doxorubicin Hydrochloride Injection Market report are 5ml/vial, 10ml/vial, 50ml/vial, Others

1 Study Coverage
1.1 Introduction to Doxorubicin Hydrochloride Injection: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Doxorubicin Hydrochloride Injection Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 5ml/vial
1.2.3 10ml/vial
1.2.4 50ml/vial
1.2.5 Others
1.3 Market Segmentation by Application
1.3.1 Global Doxorubicin Hydrochloride Injection Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Specialty Clinics
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Doxorubicin Hydrochloride Injection Revenue Estimates and Forecasts 2020-2031
2.2 Global Doxorubicin Hydrochloride Injection Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Doxorubicin Hydrochloride Injection Sales Estimates and Forecasts 2020-2031
2.4 Global Doxorubicin Hydrochloride Injection Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Doxorubicin Hydrochloride Injection Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Doxorubicin Hydrochloride Injection Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 5ml/vial Market Size by Manufacturers
3.5.2 10ml/vial Market Size by Manufacturers
3.5.3 50ml/vial Market Size by Manufacturers
3.5.4 Others Market Size by Manufacturers
3.6 Global Doxorubicin Hydrochloride Injection Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Doxorubicin Hydrochloride Injection Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Doxorubicin Hydrochloride Injection Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Doxorubicin Hydrochloride Injection Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Doxorubicin Hydrochloride Injection Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Doxorubicin Hydrochloride Injection Sales and Revenue by Type (2020-2031)
6.4 North America Doxorubicin Hydrochloride Injection Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Doxorubicin Hydrochloride Injection Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Doxorubicin Hydrochloride Injection Sales and Revenue by Type (2020-2031)
7.4 Europe Doxorubicin Hydrochloride Injection Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Doxorubicin Hydrochloride Injection Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Doxorubicin Hydrochloride Injection Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Doxorubicin Hydrochloride Injection Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Doxorubicin Hydrochloride Injection Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Doxorubicin Hydrochloride Injection Sales and Revenue by Type (2020-2031)
9.4 Central and South America Doxorubicin Hydrochloride Injection Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Doxorubicin Hydrochloride Injection Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Doxorubicin Hydrochloride Injection Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Doxorubicin Hydrochloride Injection Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Doxorubicin Hydrochloride Injection Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Hikma
11.1.1 Hikma Corporation Information
11.1.2 Hikma Business Overview
11.1.3 Hikma Doxorubicin Hydrochloride Injection Product Models, Descriptions and Specifications
11.1.4 Hikma Doxorubicin Hydrochloride Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Hikma Doxorubicin Hydrochloride Injection Sales by Product in 2024
11.1.6 Hikma Doxorubicin Hydrochloride Injection Sales by Application in 2024
11.1.7 Hikma Doxorubicin Hydrochloride Injection Sales by Geographic Area in 2024
11.1.8 Hikma Doxorubicin Hydrochloride Injection SWOT Analysis
11.1.9 Hikma Recent Developments
11.2 Pfizer
11.2.1 Pfizer Corporation Information
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Doxorubicin Hydrochloride Injection Product Models, Descriptions and Specifications
11.2.4 Pfizer Doxorubicin Hydrochloride Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Pfizer Doxorubicin Hydrochloride Injection Sales by Product in 2024
11.2.6 Pfizer Doxorubicin Hydrochloride Injection Sales by Application in 2024
11.2.7 Pfizer Doxorubicin Hydrochloride Injection Sales by Geographic Area in 2024
11.2.8 Pfizer Doxorubicin Hydrochloride Injection SWOT Analysis
11.2.9 Pfizer Recent Developments
11.3 Fresenius Kabi
11.3.1 Fresenius Kabi Corporation Information
11.3.2 Fresenius Kabi Business Overview
11.3.3 Fresenius Kabi Doxorubicin Hydrochloride Injection Product Models, Descriptions and Specifications
11.3.4 Fresenius Kabi Doxorubicin Hydrochloride Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Fresenius Kabi Doxorubicin Hydrochloride Injection Sales by Product in 2024
11.3.6 Fresenius Kabi Doxorubicin Hydrochloride Injection Sales by Application in 2024
11.3.7 Fresenius Kabi Doxorubicin Hydrochloride Injection Sales by Geographic Area in 2024
11.3.8 Fresenius Kabi Doxorubicin Hydrochloride Injection SWOT Analysis
11.3.9 Fresenius Kabi Recent Developments
11.4 Mylan
11.4.1 Mylan Corporation Information
11.4.2 Mylan Business Overview
11.4.3 Mylan Doxorubicin Hydrochloride Injection Product Models, Descriptions and Specifications
11.4.4 Mylan Doxorubicin Hydrochloride Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Mylan Doxorubicin Hydrochloride Injection Sales by Product in 2024
11.4.6 Mylan Doxorubicin Hydrochloride Injection Sales by Application in 2024
11.4.7 Mylan Doxorubicin Hydrochloride Injection Sales by Geographic Area in 2024
11.4.8 Mylan Doxorubicin Hydrochloride Injection SWOT Analysis
11.4.9 Mylan Recent Developments
11.5 Sagent
11.5.1 Sagent Corporation Information
11.5.2 Sagent Business Overview
11.5.3 Sagent Doxorubicin Hydrochloride Injection Product Models, Descriptions and Specifications
11.5.4 Sagent Doxorubicin Hydrochloride Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Sagent Doxorubicin Hydrochloride Injection Sales by Product in 2024
11.5.6 Sagent Doxorubicin Hydrochloride Injection Sales by Application in 2024
11.5.7 Sagent Doxorubicin Hydrochloride Injection Sales by Geographic Area in 2024
11.5.8 Sagent Doxorubicin Hydrochloride Injection SWOT Analysis
11.5.9 Sagent Recent Developments
11.6 Teva
11.6.1 Teva Corporation Information
11.6.2 Teva Business Overview
11.6.3 Teva Doxorubicin Hydrochloride Injection Product Models, Descriptions and Specifications
11.6.4 Teva Doxorubicin Hydrochloride Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Teva Recent Developments
11.7 AdvaCare Pharma
11.7.1 AdvaCare Pharma Corporation Information
11.7.2 AdvaCare Pharma Business Overview
11.7.3 AdvaCare Pharma Doxorubicin Hydrochloride Injection Product Models, Descriptions and Specifications
11.7.4 AdvaCare Pharma Doxorubicin Hydrochloride Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 AdvaCare Pharma Recent Developments
11.8 TAJ Pharma
11.8.1 TAJ Pharma Corporation Information
11.8.2 TAJ Pharma Business Overview
11.8.3 TAJ Pharma Doxorubicin Hydrochloride Injection Product Models, Descriptions and Specifications
11.8.4 TAJ Pharma Doxorubicin Hydrochloride Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 TAJ Pharma Recent Developments
11.9 Getwell Pharma
11.9.1 Getwell Pharma Corporation Information
11.9.2 Getwell Pharma Business Overview
11.9.3 Getwell Pharma Doxorubicin Hydrochloride Injection Product Models, Descriptions and Specifications
11.9.4 Getwell Pharma Doxorubicin Hydrochloride Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Getwell Pharma Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Doxorubicin Hydrochloride Injection Industry Chain
12.2 Doxorubicin Hydrochloride Injection Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Doxorubicin Hydrochloride Injection Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Doxorubicin Hydrochloride Injection Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Doxorubicin Hydrochloride Injection Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Doxorubicin Hydrochloride Injection Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
Fresenius Kabi
Mylan NV
TEVA
Advacare Pharma
Taj Pharma
Getwell Pharma
List of Tables
 Table 1. Global Doxorubicin Hydrochloride Injection Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Doxorubicin Hydrochloride Injection Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Doxorubicin Hydrochloride Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Doxorubicin Hydrochloride Injection Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Doxorubicin Hydrochloride Injection Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Global Doxorubicin Hydrochloride Injection Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Dose)
 Table 7. Global Doxorubicin Hydrochloride Injection Sales by Region (2020-2025) & (K Dose)
 Table 8. Global Doxorubicin Hydrochloride Injection Sales by Region (2026-2031) & (K Dose)
 Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 10. Global Doxorubicin Hydrochloride Injection Sales by Manufacturers (2020-2025) & (K Dose)
 Table 11. Global Doxorubicin Hydrochloride Injection Sales Share by Manufacturers (2020-2025)
 Table 12. Global Doxorubicin Hydrochloride Injection Revenue by Manufacturers (2020-2025) & (US$ Million)
 Table 13. Global Doxorubicin Hydrochloride Injection Revenue Market Share by Manufacturers (2020-2025)
 Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 15. Global Doxorubicin Hydrochloride Injection by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Doxorubicin Hydrochloride Injection as of 2024)
 Table 16. Global Doxorubicin Hydrochloride Injection Average Gross Margin (%) by Manufacturer (2020 VS 2024)
 Table 17. Global Doxorubicin Hydrochloride Injection Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Dose)
 Table 18. Key Manufacturers Doxorubicin Hydrochloride Injection Manufacturing Base and Headquarters
 Table 19. Global Doxorubicin Hydrochloride Injection Market Concentration Ratio (CR5 and HHI)
 Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 22. Global Doxorubicin Hydrochloride Injection Sales by Type (2020-2025) & (K Dose)
 Table 23. Global Doxorubicin Hydrochloride Injection Sales by Type (2026-2031) & (K Dose)
 Table 24. Global Doxorubicin Hydrochloride Injection Revenue by Type (2020-2025) & (US$ Million)
 Table 25. Global Doxorubicin Hydrochloride Injection Revenue by Type (2026-2031) & (US$ Million)
 Table 26. Global Doxorubicin Hydrochloride Injection ASP by Type (2020-2031) & (US$/Dose)
 Table 27. Technical Specifications by Key Product Type
 Table 28. Global Doxorubicin Hydrochloride Injection Sales by Application (2020-2025) & (K Dose)
 Table 29. Global Doxorubicin Hydrochloride Injection Sales by Application (2026-2031) & (K Dose)
 Table 30. Doxorubicin Hydrochloride Injection High-Growth Sectors Demand CAGR (2024-2031)
 Table 31. Global Doxorubicin Hydrochloride Injection Revenue by Application (2020-2025) & (US$ Million)
 Table 32. Global Doxorubicin Hydrochloride Injection Revenue by Application (2026-2031) & (US$ Million)
 Table 33. Global Doxorubicin Hydrochloride Injection ASP by Application (2020-2031) & (US$/Dose)
 Table 34. Top Customers by Region
 Table 35. Top Customers by Application
 Table 36. North America Doxorubicin Hydrochloride Injection Growth Accelerators and Market Barriers
 Table 37. North America Doxorubicin Hydrochloride Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 38. North America Doxorubicin Hydrochloride Injection Sales (K Dose) by Country (2020 VS 2024 VS 2031)
 Table 39. Europe Doxorubicin Hydrochloride Injection Growth Accelerators and Market Barriers
 Table 40. Europe Doxorubicin Hydrochloride Injection Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Europe Doxorubicin Hydrochloride Injection Sales (K Dose) by Country (2020 VS 2024 VS 2031)
 Table 42. Asia-Pacific Doxorubicin Hydrochloride Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 43. Asia-Pacific Doxorubicin Hydrochloride Injection Sales (K Dose) by Country (2020 VS 2024 VS 2031)
 Table 44. Asia-Pacific Doxorubicin Hydrochloride Injection Growth Accelerators and Market Barriers
 Table 45. Southeast Asia Doxorubicin Hydrochloride Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Central and South America Doxorubicin Hydrochloride Injection Investment Opportunities and Key Challenges
 Table 47. Central and South America Doxorubicin Hydrochloride Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 48. Middle East and Africa Doxorubicin Hydrochloride Injection Investment Opportunities and Key Challenges
 Table 49. Middle East and Africa Doxorubicin Hydrochloride Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 50. Hikma Corporation Information
 Table 51. Hikma Description and Major Businesses
 Table 52. Hikma Product Models, Descriptions and Specifications
 Table 53. Hikma Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 54. Hikma Sales Value Proportion by Product in 2024
 Table 55. Hikma Sales Value Proportion by Application in 2024
 Table 56. Hikma Sales Value Proportion by Geographic Area in 2024
 Table 57. Hikma Doxorubicin Hydrochloride Injection SWOT Analysis
 Table 58. Hikma Recent Developments
 Table 59. Pfizer Corporation Information
 Table 60. Pfizer Description and Major Businesses
 Table 61. Pfizer Product Models, Descriptions and Specifications
 Table 62. Pfizer Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 63. Pfizer Sales Value Proportion by Product in 2024
 Table 64. Pfizer Sales Value Proportion by Application in 2024
 Table 65. Pfizer Sales Value Proportion by Geographic Area in 2024
 Table 66. Pfizer Doxorubicin Hydrochloride Injection SWOT Analysis
 Table 67. Pfizer Recent Developments
 Table 68. Fresenius Kabi Corporation Information
 Table 69. Fresenius Kabi Description and Major Businesses
 Table 70. Fresenius Kabi Product Models, Descriptions and Specifications
 Table 71. Fresenius Kabi Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 72. Fresenius Kabi Sales Value Proportion by Product in 2024
 Table 73. Fresenius Kabi Sales Value Proportion by Application in 2024
 Table 74. Fresenius Kabi Sales Value Proportion by Geographic Area in 2024
 Table 75. Fresenius Kabi Doxorubicin Hydrochloride Injection SWOT Analysis
 Table 76. Fresenius Kabi Recent Developments
 Table 77. Mylan Corporation Information
 Table 78. Mylan Description and Major Businesses
 Table 79. Mylan Product Models, Descriptions and Specifications
 Table 80. Mylan Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 81. Mylan Sales Value Proportion by Product in 2024
 Table 82. Mylan Sales Value Proportion by Application in 2024
 Table 83. Mylan Sales Value Proportion by Geographic Area in 2024
 Table 84. Mylan Doxorubicin Hydrochloride Injection SWOT Analysis
 Table 85. Mylan Recent Developments
 Table 86. Sagent Corporation Information
 Table 87. Sagent Description and Major Businesses
 Table 88. Sagent Product Models, Descriptions and Specifications
 Table 89. Sagent Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 90. Sagent Sales Value Proportion by Product in 2024
 Table 91. Sagent Sales Value Proportion by Application in 2024
 Table 92. Sagent Sales Value Proportion by Geographic Area in 2024
 Table 93. Sagent Doxorubicin Hydrochloride Injection SWOT Analysis
 Table 94. Sagent Recent Developments
 Table 95. Teva Corporation Information
 Table 96. Teva Description and Major Businesses
 Table 97. Teva Product Models, Descriptions and Specifications
 Table 98. Teva Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 99. Teva Recent Developments
 Table 100. AdvaCare Pharma Corporation Information
 Table 101. AdvaCare Pharma Description and Major Businesses
 Table 102. AdvaCare Pharma Product Models, Descriptions and Specifications
 Table 103. AdvaCare Pharma Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 104. AdvaCare Pharma Recent Developments
 Table 105. TAJ Pharma Corporation Information
 Table 106. TAJ Pharma Description and Major Businesses
 Table 107. TAJ Pharma Product Models, Descriptions and Specifications
 Table 108. TAJ Pharma Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 109. TAJ Pharma Recent Developments
 Table 110. Getwell Pharma Corporation Information
 Table 111. Getwell Pharma Description and Major Businesses
 Table 112. Getwell Pharma Product Models, Descriptions and Specifications
 Table 113. Getwell Pharma Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 114. Getwell Pharma Recent Developments
 Table 115. Key Raw Materials Distribution
 Table 116. Raw Materials Key Suppliers
 Table 117. Critical Raw Material Supplier Concentration (2024) & Risk Index
 Table 118. Milestones in Production Technology Evolution
 Table 119. Distributors List
 Table 120. Market Trends and Market Evolution
 Table 121. Market Drivers and Opportunities
 Table 122. Market Challenges, Risks, and Restraints
 Table 123. Research Programs/Design for This Report
 Table 124. Key Data Information from Secondary Sources
 Table 125. Key Data Information from Primary Sources


List of Figures
 Figure 1. Doxorubicin Hydrochloride Injection Product Picture
 Figure 2. Global Doxorubicin Hydrochloride Injection Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. 5ml/vial Product Picture
 Figure 4. 10ml/vial Product Picture
 Figure 5. 50ml/vial Product Picture
 Figure 6. Others Product Picture
 Figure 7. Global Doxorubicin Hydrochloride Injection Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 8. Hospital
 Figure 9. Specialty Clinics
 Figure 10. Others
 Figure 11. Doxorubicin Hydrochloride Injection Report Years Considered
 Figure 12. Global Doxorubicin Hydrochloride Injection Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global Doxorubicin Hydrochloride Injection Revenue (2020-2031) & (US$ Million)
 Figure 14. Global Doxorubicin Hydrochloride Injection Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 15. Global Doxorubicin Hydrochloride Injection Revenue Market Share by Region (2020-2031)
 Figure 16. Global Doxorubicin Hydrochloride Injection Sales (2020-2031) & (K Dose)
 Figure 17. Global Doxorubicin Hydrochloride Injection Sales (CAGR) by Region (2020-2031) (K Dose)
 Figure 18. Global Doxorubicin Hydrochloride Injection Sales Market Share by Region (2020-2031)
 Figure 19. Top 5 and Top 10 Manufacturers Doxorubicin Hydrochloride Injection Sales Volume Market Share in 2024
 Figure 20. Global Doxorubicin Hydrochloride Injection Revenue Market Share Ranking (2024)
 Figure 21. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 22. 5ml/vial Revenue Market Share by Manufacturer in 2024
 Figure 23. 10ml/vial Revenue Market Share by Manufacturer in 2024
 Figure 24. 50ml/vial Revenue Market Share by Manufacturer in 2024
 Figure 25. Others Revenue Market Share by Manufacturer in 2024
 Figure 26. Global Doxorubicin Hydrochloride Injection Sales Market Share by Type (2020-2031)
 Figure 27. Global Doxorubicin Hydrochloride Injection Revenue Market Share by Type (2020-2031)
 Figure 28. Global Doxorubicin Hydrochloride Injection Sales Market Share by Application (2020-2031)
 Figure 29. Global Doxorubicin Hydrochloride Injection Revenue Market Share by Application (2020-2031)
 Figure 30. North America Doxorubicin Hydrochloride Injection Sales YoY (2020-2031) & (K Dose)
 Figure 31. North America Doxorubicin Hydrochloride Injection Revenue YoY (2020-2031) & (US$ Million)
 Figure 32. North America Top 5 Manufacturers Doxorubicin Hydrochloride Injection Sales Revenue (US$ Million) in 2024
 Figure 33. North America Doxorubicin Hydrochloride Injection Sales Volume (K Dose) by Type (2020- 2031)
 Figure 34. North America Doxorubicin Hydrochloride Injection Sales Revenue (US$ Million) by Type (2020 - 2031)
 Figure 35. North America Doxorubicin Hydrochloride Injection Sales Volume (K Dose) by Application (2020-2031)
 Figure 36. North America Doxorubicin Hydrochloride Injection Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 37. US Doxorubicin Hydrochloride Injection Revenue (2020-2031) & (US$ Million)
 Figure 38. Canada Doxorubicin Hydrochloride Injection Revenue (2020-2031) & (US$ Million)
 Figure 39. Mexico Doxorubicin Hydrochloride Injection Revenue (2020-2031) & (US$ Million)
 Figure 40. Europe Doxorubicin Hydrochloride Injection Sales YoY (2020-2031) & (K Dose)
 Figure 41. Europe Doxorubicin Hydrochloride Injection Revenue YoY (2020-2031) & (US$ Million)
 Figure 42. Europe Top 5 Manufacturers Doxorubicin Hydrochloride Injection Sales Revenue (US$ Million) in 2024
 Figure 43. Europe Doxorubicin Hydrochloride Injection Sales Volume (K Dose) by Type (2020-2031)
 Figure 44. Europe Doxorubicin Hydrochloride Injection Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 45. Europe Doxorubicin Hydrochloride Injection Sales Volume (K Dose) by Application (2020-2031)
 Figure 46. Europe Doxorubicin Hydrochloride Injection Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 47. Germany Doxorubicin Hydrochloride Injection Revenue (2020-2031) & (US$ Million)
 Figure 48. France Doxorubicin Hydrochloride Injection Revenue (2020-2031) & (US$ Million)
 Figure 49. U.K. Doxorubicin Hydrochloride Injection Revenue (2020-2031) & (US$ Million)
 Figure 50. Italy Doxorubicin Hydrochloride Injection Revenue (2020-2031) & (US$ Million)
 Figure 51. Russia Doxorubicin Hydrochloride Injection Revenue (2020-2031) & (US$ Million)
 Figure 52. Asia-Pacific Doxorubicin Hydrochloride Injection Sales YoY (2020-2031) & (K Dose)
 Figure 53. Asia-Pacific Doxorubicin Hydrochloride Injection Revenue YoY (2020-2031) & (US$ Million)
 Figure 54. Asia-Pacific Top 8 Manufacturers Doxorubicin Hydrochloride Injection Sales Revenue (US$ Million) in 2024
 Figure 55. Asia-Pacific Doxorubicin Hydrochloride Injection Sales Volume (K Dose) by Type (2020- 2031)
 Figure 56. Asia-Pacific Doxorubicin Hydrochloride Injection Sales Revenue (US$ Million) by Type (2020- 2031)
 Figure 57. Asia-Pacific Doxorubicin Hydrochloride Injection Sales Volume (K Dose) by Application (2020-2031)
 Figure 58. Asia-Pacific Doxorubicin Hydrochloride Injection Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 59. Indonesia Doxorubicin Hydrochloride Injection Revenue (2020-2031) & (US$ Million)
 Figure 60. Japan Doxorubicin Hydrochloride Injection Revenue (2020-2031) & (US$ Million)
 Figure 61. South Korea Doxorubicin Hydrochloride Injection Revenue (2020-2031) & (US$ Million)
 Figure 62. China Taiwan Doxorubicin Hydrochloride Injection Revenue (2020-2031) & (US$ Million)
 Figure 63. India Doxorubicin Hydrochloride Injection Revenue (2020-2031) & (US$ Million)
 Figure 64. Central and South America Doxorubicin Hydrochloride Injection Sales YoY (2020-2031) & (K Dose)
 Figure 65. Central and South America Doxorubicin Hydrochloride Injection Revenue YoY (2020-2031) & (US$ Million)
 Figure 66. Central and South America Top 5 Manufacturers Doxorubicin Hydrochloride Injection Sales Revenue (US$ Million) in 2024
 Figure 67. Central and South America Doxorubicin Hydrochloride Injection Sales Volume (K Dose) by Type (2021-2031)
 Figure 68. Central and South America Doxorubicin Hydrochloride Injection Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 69. Central and South America Doxorubicin Hydrochloride Injection Sales Volume (K Dose) by Application (2020-2031)
 Figure 70. Central and South America Doxorubicin Hydrochloride Injection Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 71. Brazil Doxorubicin Hydrochloride Injection Revenue (2020-2025) & (US$ Million)
 Figure 72. Argentina Doxorubicin Hydrochloride Injection Revenue (2020-2025) & (US$ Million)
 Figure 73. Middle East, and Africa Doxorubicin Hydrochloride Injection Sales YoY (2020-2031) & (K Dose)
 Figure 74. Middle East and Africa Doxorubicin Hydrochloride Injection Revenue YoY (2020-2031) & (US$ Million)
 Figure 75. Middle East and Africa Top 5 Manufacturers Doxorubicin Hydrochloride Injection Sales Revenue (US$ Million) in 2024
 Figure 76. Middle East and Africa Doxorubicin Hydrochloride Injection Sales Volume (K Dose) by Type (2021-2031)
 Figure 77. South America Doxorubicin Hydrochloride Injection Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 78. Middle East and Africa Doxorubicin Hydrochloride Injection Sales Volume (K Dose) by Application (2020-2031)
 Figure 79. Middle East and Africa Doxorubicin Hydrochloride Injection Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 80. GCC Countries Doxorubicin Hydrochloride Injection Revenue (2020-2025) & (US$ Million)
 Figure 81. Turkey Doxorubicin Hydrochloride Injection Revenue (2020-2025) & (US$ Million)
 Figure 82. Egypt Doxorubicin Hydrochloride Injection Revenue (2020-2025) & (US$ Million)
 Figure 83. South Africa Doxorubicin Hydrochloride Injection Revenue (2020-2025) & (US$ Million)
 Figure 84. Doxorubicin Hydrochloride Injection Industry Chain Mapping
 Figure 85. Regional Doxorubicin Hydrochloride Injection Manufacturing Base Distribution (%)
 Figure 86. Global Doxorubicin Hydrochloride Injection Production Market Share by Region (2020-2031)
 Figure 87. Doxorubicin Hydrochloride Injection Production Process
 Figure 88. Regional Doxorubicin Hydrochloride Injection Production Cost Structure
 Figure 89. Channels of Distribution (Direct Vs Distribution)
 Figure 90. Bottom-up and Top-down Approaches for This Report
 Figure 91. Data Triangulation
 Figure 92. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SecuX Technology Inc

SIMILAR REPORTS

Global Doxorubicin Injection Market Research Report 2024
Global Idarubicin Hydrochloride for Injection Market Research Report 2024
Global Doxorubicin Hydrochloride Market Research Report 2024
Global Daunorubicin Hydrochloride Injection Market Research Report 2025
Global Doxorubicin Hydrochloride API Market Research Report 2024
Global Epirubicin Hydrochloride Market Research Report 2025
Global Epirubicin Hydrochloride Injection Market Research Report 2025
Global Aclarubicin Hydrochlorid For Injection Market Research Report 2024
Global Pirarubicin Hydrochloride for Injection Market Research Report 2024
Anthracyclines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Oncology Injection Drug Market Research Report 2025
Liposomal Doxorubicin Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Irinotecan Hydrochloride Injection Market Research Report 2025
Global Bendamustine Hydrochloride Injection Market Research Report 2025
Global Cytarabine Hydrochloride for Injection Market Research Report 2024
Global Chemotherapy Inject Medicine Pump Market Research Report 2024
Global Mitoxantrone Injection Market Research Report 2024
Global Anti tumor Injection Market Research Report 2024
Global Breast Cancer Treatment Drugs Market Insights Forecast to 2030
Global Amiodarone Hydrochloride Injection Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions